- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03755518
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)
A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib.
The primary objective of the study is to evaluate the percentage of subjects with at least a 35% reduction in spleen size and one of the secondary objectives is to evaluate the safety of fedratinib.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib.
The spleen volume reduction at the end of Cycle 6 as the primary objective. The secondary objectives of the study are to further evaluate the safety and to assess and implement mitigation strategies for WE and for gastrointestinal (GI) adverse events.
The study will be at multiple centers to provide access to a broad population and have assurance the results are likely to have general applicability.
This is also conducted as an open-label study to collect efficacy and safety data with fedratinib use, no randomization or stratification will occur.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Expanded Access
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 2A5
- Local Institution - 203
-
-
Ontario
-
London, Ontario, Canada, N6C 6B5
- Local Institution - 207
-
Ottawa, Ontario, Canada, K1H 8L6
- Local Institution - 205
-
Toronto, Ontario, Canada, M5G 2M9
- Local Institution - 200
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Local Institution - 202
-
Montreal, Quebec, Canada, H1T 2M4
- Local Institution - 201
-
Sherbrooke, Quebec, Canada, J1K 2R1
- Local Institution - 204
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Local Institution - 117
-
-
Florida
-
Miami, Florida, United States, 33176
- Local Institution - 126
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Local Institution - 113
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Local Institution - 112
-
Chicago, Illinois, United States, 60637
- Local Institution - 109
-
Park Ridge, Illinois, United States, 60068
- Local Institution - 121
-
-
Kansas
-
Kansas City, Kansas, United States, 66160-7314
- Local Institution - 100
-
-
Maryland
-
Baltimore, Maryland, United States, 21229-5299
- Local Institution - 123
-
Bethesda, Maryland, United States, 20817
- Local Institution - 118
-
Columbia, Maryland, United States, 21044
- Local Institution - 127
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Local Institution - 103
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Local Institution - 101
-
-
New Jersey
-
Newark, New Jersey, United States, 07112-2027
- Local Institution - 128
-
-
New York
-
Brooklyn, New York, United States, 11212
- Local Institution - 130
-
New York, New York, United States, 10029
- Local Institution - 115
-
New York, New York, United States, 10032
- Local Institution - 124
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Local Institution - 105
-
Durham, North Carolina, United States, 27705
- Local Institution - 114
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Local Institution - 111
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Local Institution - 106
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Local Institution - 108
-
-
Texas
-
Dallas, Texas, United States, 75390-8852
- Local Institution - 119
-
Fort Worth, Texas, United States, 76104
- Local Institution - 132
-
Houston, Texas, United States, 77303
- Local Institution - 110
-
San Antonio, Texas, United States, 78229
- Local Institution - 120
-
-
Washington
-
Seattle, Washington, United States, 98109
- Local Institution - 116
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-2454
- Local Institution - 129
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Main Study Inclusion Criteria
- Subject is at least 18 years of age at the time of signing the informed consent form (ICF)
- Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2
- Subject has diagnosis of primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-ET or post-PV myelofibrosis according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report
- Subject has a DIPSS Risk score of Intermediate or High
- Subject has a measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥ 450 cm3 by MRI or CT-scan assessment or by palpable spleen measuring ≥ 5 cm below the left costal margin.
Subject has been previously exposed to ruxolitinib, while diagnosed with MF (PMF, post-ET MF or post-PV MF), and must meet at least one of the following criteria (a or b)
- Treatment with ruxolitinib for ≥ 3 months
Treatment with ruxolitinib for ≥ 28 days complicated by any of the following:
- Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months) or
- Grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while on treatment with ruxolitinib
- Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to fedratinib treatment.
- Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
- Subject is willing and able to adhere to the study visit schedule and other protocol requirements
- Participants must agree to use effective contraception
Exclusion Criteria:
Main Study Exclusion Criteria
Any of the following laboratory abnormalities:
- Platelets < 50,000/μL
- Absolute neutrophil count (ANC) < 1.0 x 109/L
- White blood count (WBC) > 100 x 10^9/L
- Myeloblasts > 5 % in peripheral blood
- Estimated glomerular filtration rate < 30 mL/min/1.73 m^2 (as per the Modification of Diet in Renal Disease [MDRD] formula)
- Serum amylase or lipase > 1.5 x ULN (upper limit of normal)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x ULN
- Total bilirubin > 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN are eligible if the direct bilirubin fraction is < 25% of the total bilirubin
- Subject is pregnant or lactating female
- Subject with previous splenectomy
- Subject with previous or planned hematopoietic cell transplant
- Subject with prior history of encephalopathy, including Wernicke's
- Subject with signs or symptoms of encephalopathy including Wernicke's (eg, severe ataxia, ocular paralysis or cerebellar signs)
- Subject with thiamine deficiency, defined as thiamine levels in whole blood below normal range according to institutional standard and not corrected prior to enrollment on the study
- Subject with concomitant treatment with or use of pharmaceutical, herbal agents or food known to be strong or moderate inducers of Cytochrome P450 3A4 (CYP3A4), or dual CYP2C19 and CYP3A4 inhibitors
- Subject on any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), anagrelide, immunosuppressive therapy, systemic corticosteroids > 10 mg/day prednisone or equivalent. Subjects who have had prior exposure to hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to the start of fedratinib treatment
- Subject has received ruxolitinib within 14 days prior to the start of fedratinib
- Subject on treatment with myeloid growth factor (eg, granulocyte-colony stimulating factor [G-CSF]) within 14 days prior to the start of fedratinib treatment
- Subject with previous exposure to Janus kinase (JAK) inhibitor(s) for more than 1 cycle other than ruxolitinib treatment
- Subject on treatment with aspirin with doses > 150 mg daily
- Subject with major surgery within 28 days before starting fedratinib treatment
- Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, non-alcoholic steatohepatitis)
Subject with prior malignancy other than the disease under study unless the subject has not required treatment for the malignancy for at least 3 years prior to enrollment.
However, subject with the following history/concurrent conditions provided successfully treated may enroll: non-invasive skin cancer, in situ cervical cancer, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system), or is free of disease and on hormonal treatment only
- Subject with uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4)
- Subject with known human immunodeficiency virus (HIV), known active infectious Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC)
- Subject with serious active infection
- Subject with presence of any significant gastric or other disorder that would inhibit absorption of oral medication
- Subject is unable to swallow capsule
- Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
- Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
- Subject has any condition that confounds the ability to interpret data from the study
- Subject with participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to start of fedratinib treatment
- Subject with life expectancy of less than 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Administration of Fedratinib 400mg/day
Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
|
A potent and selective inhibitor of JAK2 kinase activity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Have a ≥ 35% Spleen Volume Reduction (SVR) at End of Cycle 6
Time Frame: From First Dose to end of Cycle 6 (approximately 168 days)
|
Percentage of participants who have a ≥ 35% SVR at end of Cycle 6 as compared to baseline.
Participants with a missing MRI/CT spleen volume at the end of Cycle 6 including those who meet the criteria for progression of splenomegaly before the end of Cycle 6 will be considered non-responders.
Baseline value is defined as the last value or measurement taken prior to the first dose in the study
|
From First Dose to end of Cycle 6 (approximately 168 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants of All Grade Adverse Events (AEs) and Grade 3/4 AEs
Time Frame: From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 128 weeks)
|
Number of participants and severity of all grade adverse events (AEs) and grade 3/4 AEs as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.
|
From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 128 weeks)
|
Number of Participants and Severity of Treatment Related All Grade Adverse Events (AEs) and Grade 3/4 AEs
Time Frame: From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 124 weeks)
|
Number of participants and severity of treatment related all grade adverse events (AEs) and grade 3/4 AEs as per NCI CTCAE.
|
From first dose up to 30 days post last dose. (an average of 50.3 weeks up to a maximum of 124 weeks)
|
Mean Change From Baseline in Hematology Laboratory Analysis - Hemoglobin
Time Frame: at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean change from baseline in hematology laboratory analysis - hemoglobin
|
at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean Change From Baseline in Hematology Laboratory Analysis - Erythrocytes
Time Frame: at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean change from baseline in hematology laboratory analysis - erythrocytes. Baseline value is defined as the last value or measurement taken prior to the first dose in the study |
at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean Change From Baseline in Hematology Laboratory Analysis - Platelets, Leukocytes and Neutrophils
Time Frame: at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean change from baseline in hematology laboratory analysis - platelets, leukocytes and neutrophils. Baseline value is defined as the last value or measurement taken prior to the first dose in the study |
at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean Change From Baseline in the Percentage of Blasts/Leukocytes in Hematology Laboratory Analysis
Time Frame: at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean change from baseline in hematology laboratory analysis - blasts/leukocytes Baseline value is defined as the last value or measurement taken prior to the first dose in the study |
at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean Change From Baseline in Chemistry Parameters Analysis - ALT, AST, Amylase, Lipase
Time Frame: at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean change from baseline in chemistry parameters analysis - ALT, AST, Amylase, Lipase Baseline value is defined as the last value or measurement taken prior to the first dose in the study |
at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean Change From Baseline in Chemistry Parameters Analysis - Creatinine
Time Frame: at Cycle 4 Day 1 and Cycle 7 Day 1
|
Mean change from baseline in chemistry parameters analysis - Creatinine. Baseline value is defined as the last value or measurement taken prior to the first dose in the study |
at Cycle 4 Day 1 and Cycle 7 Day 1
|
Spleen Response Rate by Palpation
Time Frame: From First Dose to end of Cycle 6 (approximately 168 days)
|
Spleen response rate by palpation is the percentage of participants with a spleen response according to the IWG-MRT 2013 at the end of Cycle 6 as compared to baseline.
This will be calculated for participants that have an enlarged spleen (≥ 5 cm below LCM) at baseline.
Participants with a missing spleen size assessment at the end of Cycle 6 including those who meet the criteria for progression of splenomegaly before the end of Cycle 6 will be considered not to be responders.
|
From First Dose to end of Cycle 6 (approximately 168 days)
|
Symptom Response Rate
Time Frame: From First Dose to end of Cycle 6 (approximately 168 days)
|
Symptom response rate (SRR) is defined as the percentage of participants with ≥ 50% reduction from baseline to the end of Cycle 6 in total symptom score (TSS) measured by MFSAF version 4.0.
The TSS will be defined as the sum of each of the 7 symptom scores.
Participants without a baseline TSS > 0 will be considered non-evaluable (due to no place for symptom reduction) for the SRR analysis.
Participants with a missing TSS at the end of Cycle 6 or who had disease progression before the end of the Cycle 6 will be considered non-responders.
|
From First Dose to end of Cycle 6 (approximately 168 days)
|
Durability of Spleen Volume Response by MRI/CT (DR)
Time Frame: From First Dose to end of Cycle 6 (approximately 168 days)
|
Durability of spleen volume response (DR) by MRI/CT is defined as time from the first documented spleen response (ie, ≥ 35% reduction in spleen volume) to the date of subsequent progressive disease (PD) (ie, ≥ 25% increase in spleen volume from baseline) or death, whichever is earlier.
In the absence an event (ie, subsequent spleen volume reduction < 35% before the analysis is performed), the DR will be censored at the date of the last valid assessment performed before the analysis performed date.
Durability of spleen volume response by MRI/CT scan will be analyzed using Kaplan-Meier method.
|
From First Dose to end of Cycle 6 (approximately 168 days)
|
Durability of Spleen Response by Palpation (DRP)
Time Frame: From First Dose to end of Cycle 6 (approximately 168 days)
|
Durability of spleen response by palpation (DRP) is defined as time from the date of first documented palpable spleen response, according to the IWG-MRT 2013 to the date of subsequent PD according to the IWG-MRT 2013 or death, whichever is earlier.
Durability of spleen response by palpation according to the IWG-MRT 2013 criteria will be calculated for subjects that have an enlarged spleen at baseline (≥ 5 cm below LCM), and that have a spleen response by palpation.
In the absence of an event (ie, no loss of spleen response by palpation) before the analysis is performed, the DRP will be censored at the date of the last valid assessment performed before the analysis performed date.
Durability of spleen response by palpation will be analyzed using Kaplan-Meier (K-M) method.
|
From First Dose to end of Cycle 6 (approximately 168 days)
|
Durability of Symptom Response (DSR)
Time Frame: From First Dose to end of Cycle 6 (approximately 168 days)
|
Durability of symptoms response is defined as time from the first documented response in TSS (ie, reduction in TSS ≥ 50%) measured by MFSAF version 4.0 to the first documented TSS reduction < 50%.
In the absence of TSS reduction < 50% before the analysis performed, the DSR will be censored at the date of the last valid assessment performed before the analysis performed date.
|
From First Dose to end of Cycle 6 (approximately 168 days)
|
Number of Participants With Grade 3 or Higher AEs: Nausea, Vomiting, Diarrhea and Encephalopathy Including Wernicke's.
Time Frame: From first dose to end of treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
|
Number of participants with grade 3 or higher AEs: Nausea, Vomiting, Diarrhea and Encephalopathy including Wernicke's.
|
From first dose to end of treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
|
Number of Participants With Thiamine Levels < Lower Limit of Normal (LLN).
Time Frame: At Screening, Cycle 1, 2, 3, 6, 9, 15, 18, 21, 24, 27, 30 and End of Treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
|
Number of participants with thiamine levels < LLN. LLN of thiamine is 70 nmol/L. |
At Screening, Cycle 1, 2, 3, 6, 9, 15, 18, 21, 24, 27, 30 and End of Treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
|
Number of Participants With Thiamine Levels > Upper Limit of Normal (ULN).
Time Frame: At Screening, Cycle 1, 2, 3, 6, 9, 15, 18, 21, 24, 27, 30 and End of Treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
|
Number of participants with thiamine levels > ULN. ULN of thiamine is 180 nmol/L. |
At Screening, Cycle 1, 2, 3, 6, 9, 15, 18, 21, 24, 27, 30 and End of Treatment (an average of 50.3 weeks up to a maximum of 124 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Primary Myelofibrosis
- Thrombocytosis
- Thrombocythemia, Essential
- Polycythemia Vera
- Polycythemia
Other Study ID Numbers
- FEDR-MF-001
- U1111-1223-2862 (Other Identifier: WHO)
- 2018-002237-38 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Myelofibrosis
-
Assaf-Harofeh Medical CenterUnknownMyelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ETIsrael
-
The University of Hong KongRecruitingMyelofibrosis | Primary Myelofibrosis, Prefibrotic StageHong Kong
-
Centre Hospitalier Annecy GenevoisCompleted
-
AbbVieRecruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
-
AbbVieTerminatedMyelofibrosis (MF)United States, Korea, Republic of, South Africa
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingModerate and High Risk MyelofibrosisChina
-
Telios Pharma, Inc.RecruitingPrimary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET MyelofibrosisSpain, United States, France, Poland, Italy, Germany
Clinical Trials on FEDRATINIB
-
Bristol-Myers SquibbRecruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisKorea, Republic of
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisItaly
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationCompletedHealthy Volunteers | Hepatic ImpairmentUnited States
-
CelgeneActive, not recruiting
-
Bristol-Myers SquibbCompletedHealthy VolunteersUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbRecruitingMDS | Myeloproliferative Neoplasm | Chronic Neutrophilic LeukemiaUnited States
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationAvailable
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia VeraAustralia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
-
Bristol-Myers SquibbActive, not recruitingMyelofibrosisItaly, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbRecruitingMyeloproliferative NeoplasmUnited States